Browsing Tag

Unicycive Therapeutics

Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference

Jason Junior Jul 20, 2023

LOS ALTOS, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today…

Health

Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb

Jason Junior Dec 28, 2022

Renazorb demonstrates pharmacodynamic bioequivalence to Fosrenol Renazorb’s enhanced product profile features reduced pill burden and small, swallowable tablets, which may improve patient compliance On track to file New Drug…

Health

Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of…

Jason Junior Dec 22, 2022

LOS ALTOS, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, announced today that the Medicines and…

Health

Unicycive Completes Enrollment of Pivotal Bioequivalence Study for RENAZORB™ (lanthanum…

Jason Junior Nov 10, 2022

Topline Data Expected by Year End 2022 On Track to File the NDA in 2023 LOS ALTOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for…

Health

Unicycive to Showcase Pipeline of Innovative Product Candidates at American Society of Nephrology’s…

Jason Junior Oct 26, 2022

Multiple Data Presentations Support the Company’s Pipeline of Innovative Product Candidates aimed at Improving the Quality-of-Life for Patients Battling Kidney Disease Independently Hosted Key Opinion Leader Panel to Highlight Potential…

Health

Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Acute Kidney…

Jason Junior Sep 7, 2022

Established animal model of AKI showed a statistically significant reduction of a key biomarker of kidney injury when treated with UNI-494 AKI remains a serious unmet medical need with no FDA approved drugs for its treatment On track to…

Health

Unicycive Announces Multiple Abstracts Selected for Presentation at American Society of Nephrology’s…

Jason Junior Aug 24, 2022

LOS ALTOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the acceptance of two…

Health

Unicycive Reports Key Findings from Market Research with Nephrologists

Jason Junior Jul 20, 2022

Renazorb product profile rated as best-in-class phosphate binder Nephrologists report high prescribing intent for Renazorb pending FDA approval LOS ALTOS, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. …

Health

Unicycive Initiates Pivotal Clinical Bioequivalence Study of Renazorb to Treat Hyperphosphatemia

Jason Junior Jun 2, 2022

LOS ALTOS, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease today announced the initiation of its pivotal…